ArticleAsian Pacific journal of cancer prevention : APJCP2025
Cancer Burden Across The South East Asia Nation (ASEAN) in 2022.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent advances in hormone-based biopharmaceuticals for cancer therapy.Journal of the Egyptian National Cancer Institute · 2026Review
- Bacteriology and clinical outcomes of pleural infections in Singapore: an 8-year retrospective observational study.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis article aims to estimate the cancer burden in the ASEAN region by utilizing data from the 2022 Global Cancer Observatory (GCO).
methodsUsing GCO data and its metric definition, we gathered cancer-related information for each ASEAN country and globally. Key metrics include incidence (new cases in 2022), mortality (cancer death in 2022), incidence per 100,000 (proportion diagnosed), mortality-to-incidence ratio (MIR) per 100,000 (proportion who died), age-standardized incidence rate(ASIR) per 100,000 (adjusted for age distribution), age-standardized mortality rate (ASMR) per 100,000 (adjusted mortality rate), and 5-year cancer prevalence (total cases from 2017-2022).
resultThe region accounted for 9.3% of global cancer incidence, with Singapore having the highest Age-standardized incidence rate(ASIR) at 231.1 and Myanmar the lowest at 135.5. The Philippines had the highest Age-standardized mortality rate (ASMR) at 112.9, and Indoensia the lowest at 82.5. Breast cancer was the most common among females (ASIR: 41.8), while lung cancer had the highest ASIR among males (26.0). Throid cancer had the highest incidence and mortality-to-incidence ratio in female, while liver cancer had the highest mortality rate in males. Across ASEAN, breast cancer ranked among the top five cancer in all countries. The finding highlight variations in cancer incidence and mortality across the region, emphasizing the need for targered prevention and control strategies.
conclusionData from ASEAN countries highlight significant variation in cancer incidence (ASIR) and mortality (ASMR) rate. Breasrt cancer was the most highest ASIR cancer among country in ASEAN. Cancer influenced by factor such as lifestyle habits, socioeconomic conditions, healthcare infrastructure, and genetic predispositions. Major contributors to the rising cancer rates in the region include key risk factor like tobacco and alcohol use, obesity, physical inactivity, and poor dietary habits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.